• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.

作者信息

Yi Tae Won, Wong Michelle M Y, Neuen Brendon L, Arnott Clare, Poirier Paul, Seufert Jochen, Slee April, Rapattoni Wally, Ang Fernando G, Wheeler David C, Mahaffey Kenneth W, Perkovic Vlado, Levin Adeera

机构信息

The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.

Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

出版信息

Diabetes Obes Metab. 2023 Jul;25(7):2043-2047. doi: 10.1111/dom.15065. Epub 2023 Apr 24.

DOI:10.1111/dom.15065
PMID:36974373
Abstract
摘要

相似文献

1
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.卡格列净对合并或不合并外周动脉疾病的慢性肾脏病患者心血管和肾脏事件的影响：CANVAS项目和CREDENCE试验的综合分析
Diabetes Obes Metab. 2023 Jul;25(7):2043-2047. doi: 10.1111/dom.15065. Epub 2023 Apr 24.
2
Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial.卡格列净用于心血管和肾脏的一级及二级预防：来自CANVAS项目和CREDENCE试验的见解
J Am Heart Assoc. 2024 Feb 6;13(3):e031586. doi: 10.1161/JAHA.123.031586. Epub 2024 Jan 19.
3
Renal and Cardiovascular Effects of Sodium Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease: Perspectives on the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial Results.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的肾脏和心血管影响：基于卡格列净和糖尿病肾脏疾病进展的临床评估试验结果的观点。
Am J Nephrol. 2020;51(4):276-288. doi: 10.1159/000506533. Epub 2020 Mar 13.
4
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.卡格列净对比非奈利酮对心肾结局的影响：FIDELIO-DKD 探索性事后分析与 CREDENCE 研究结果的比较。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.
5
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial.根据基线糖化血红蛋白评估卡格列净对2型糖尿病合并慢性肾脏病患者心血管和肾脏事件的影响，包括糖化血红蛋白<7%的患者：CREDENCE试验结果
Circulation. 2020 Feb 4;141(5):407-410. doi: 10.1161/CIRCULATIONAHA.119.044359. Epub 2019 Nov 11.
6
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE.根据基线时2型糖尿病治疗目标，卡格列净对心血管和肾脏结局的影响：来自CANVAS项目和CREDENCE研究的数据
Diabetes Obes Metab. 2023 Jul;25(7):2038-2042. doi: 10.1111/dom.15057. Epub 2023 Apr 4.
7
Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.基于基线估计肾小球滤过率的坎格列净对主要不良心血管事件的影响：CANVAS 项目和 CREDENCE 试验的西班牙裔亚组汇总分析。
Diabetes Obes Metab. 2022 Jan;24(1):12-20. doi: 10.1111/dom.14539. Epub 2021 Sep 23.
8
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.卡格列净对肾脏的保护作用：CANVAS 项目和 CREDENCE 试验的联合分析。
Diabetes Obes Metab. 2023 Aug;25(8):2331-2339. doi: 10.1111/dom.15112. Epub 2023 May 15.
9
[Canaglifozin results in cardiovascular and renal protection in patients with type 2 diabetes : from CANVAS to CREDENCE].[卡格列净对2型糖尿病患者具有心血管和肾脏保护作用：从CANVAS研究到CREDENCE研究]
Rev Med Liege. 2019 Oct;74(10):508-513.
10
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.卡格列净对合并糖尿病和慢性肾脏病患者心血管总负担的影响：来自 CREDENCE 试验的事后分析。
J Am Heart Assoc. 2022 Aug 16;11(16):e025045. doi: 10.1161/JAHA.121.025045. Epub 2022 Aug 5.

引用本文的文献

1
Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review.下肢外周动脉疾病患者 2 型糖尿病管理中的挑战与机遇：量身定制的诊断和治疗回顾。
Cardiovasc Diabetol. 2024 Jun 26;23(1):220. doi: 10.1186/s12933-024-02325-9.
2
Oxidative Stress: A Culprit in the Progression of Diabetic Kidney Disease.氧化应激：糖尿病肾病进展的罪魁祸首。
Antioxidants (Basel). 2024 Apr 12;13(4):455. doi: 10.3390/antiox13040455.